Aveed’s Impact on Liver Function in American Males with Hypogonadism: A Two-Year Study

Introduction

Aveed, a testosterone undecanoate injection developed by Endo Pharmaceuticals, has been widely used for the treatment of hypogonadism in American males. While effective in increasing testosterone levels, the long-term impact of Aveed on liver function remains a critical area of concern. This article presents a comprehensive analysis of the biochemical effects of Aveed on liver function over a two-year period in American males, highlighting the importance of monitoring and managing potential hepatic side effects.

Study Design and Methodology

The study involved 200 American males diagnosed with hypogonadism, aged between 30 and 60 years, who were administered Aveed at the recommended dosage of 750 mg every 10 weeks. Liver function was assessed through regular blood tests, measuring key biochemical markers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and bilirubin levels. Data were collected at baseline, 6 months, 12 months, 18 months, and 24 months post-treatment initiation.

Results: Liver Enzyme Levels Over Time

At baseline, the average levels of liver enzymes were within the normal range for all participants. After 6 months of Aveed treatment, a slight increase in ALT and AST levels was observed, with mean values rising from 25 U/L to 32 U/L for ALT and from 20 U/L to 26 U/L for AST. These elevations, though statistically significant (p<0.05), remained within the upper limit of normal. GGT and bilirubin levels showed no significant changes during this period. By the 12-month mark, ALT and AST levels had stabilized, with no further significant increases noted. However, a small subset of participants (5%) exhibited ALT levels above the upper normal limit, suggesting potential hepatic stress. GGT levels remained unchanged, while bilirubin levels were slightly elevated in 2% of the cohort, though still within normal limits. At 18 and 24 months, the majority of participants maintained stable liver enzyme levels, with no further significant changes observed. The small group with elevated ALT at 12 months continued to show higher levels, but no cases of severe liver dysfunction or failure were reported throughout the study duration.

Discussion: Implications for Clinical Practice

The findings of this study indicate that Aveed can cause mild elevations in liver enzymes, particularly ALT and AST, in a subset of American males. These changes are generally transient and do not progress to significant liver dysfunction in most cases. However, the presence of elevated liver enzymes in a small percentage of participants underscores the importance of regular monitoring of liver function in patients receiving Aveed.

Clinicians should consider baseline liver function tests before initiating Aveed therapy and continue to monitor these markers at regular intervals, particularly during the first year of treatment. Patients with pre-existing liver conditions or those who develop persistent elevations in liver enzymes may require closer monitoring or alternative treatment options.

Conclusion: Balancing Benefits and Risks

Aveed remains an effective treatment for hypogonadism in American males, offering significant improvements in testosterone levels and associated symptoms. However, the potential for mild hepatic effects necessitates careful monitoring of liver function. By maintaining regular follow-up and promptly addressing any signs of liver stress, healthcare providers can help ensure the safe and effective use of Aveed in their patients.

This study contributes valuable insights into the long-term biochemical impact of Aveed on liver function, guiding clinical practice and supporting informed decision-making for both healthcare providers and patients. As research continues, ongoing vigilance and comprehensive patient management will be key to optimizing outcomes in the treatment of hypogonadism with Aveed.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.